Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931189 | 0.93 | CYP2A6 (0.42) | CYP2A6ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3480230 | 0.81 | CYP2A6 (0.34) | CYP2A6ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3480385 | 0.73 | LMNA (0.46) | ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3480209 | 0.71 | CYP2A6 (0.51) | CYP2A6ALDH1A1MAPTHSD17B10 | |
| SCHEMBL4420015 | 0.71 | CYP2A6 (0.58) | CYP2A6ALDH1A1MAPTHSD17B10 | |
| SCHEMBL4420014 | 0.69 | CYP2A6 (0.56) | CYP2A6 | |
| SCHEMBL12980094 | 0.67 | CYP2A6 (0.54) | CYP2A6ALDH1A1 | |
| SCHEMBL31081422 | 0.66 | MAOA (0.39) | CYP2A6ALDH1A1MAPT | |
| SCHEMBL3480326 | 0.66 | ALDH1A1 (0.34) | ALDH1A1HSD17B10 | |
| SCHEMBL14931264 | 0.66 | CYP2A6 (0.37) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049200-B1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC (CA) | 2015-04-29 | — | — | EP | disclosed |
| US-8440643-B2 | Inhibitors of beta-lactamase | METHYLGENE INC. (CA) | 2013-05-14 | — | — | US | disclosed |
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | disclosed |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2049200-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MethylGene Inc. (CA) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049201-A2 | PHOSPHATE DIESTER AMIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008073142-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007147644-A2 | PHOSPHATE DIESTER AMIDES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MGAM, BPGM, PPME1 | CYP2A6 745/4885ALDH1A1 2755/4885MAPT 4576/4885 |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, MGAM2, PGLS | CYP2A6 944/4885ALDH1A1 2190/4885MAPT 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.